

Special Issue

Novel Therapeutic Targets and Drug Candidates for the Treatment of Eye Diseases

Message from the Guest Editor

Vision is an essential part of life. With an increased aging population, vision impairment has become a major global public health problem. Recent breakthroughs, including the use of the artificial intraocular lens for cataracts and anti-VEGF molecules for wet age-related macular degeneration (AMD) are some impressive examples of restoring vision. However, many unmet needs remain in the field of ocular diseases, particularly for glaucoma, diabetic retinopathy, and AMD. Moreover, due to the presence of blood–ocular barriers, ocular drug delivery has always been a challenge for ophthalmologists and pharmaceutical scientists. In this Special Issue, we invite both reviews and original research articles related to ophthalmic drug discovery. The major goal is to highlight some of the recent findings in the field, and to discuss new drug delivery technologies and possible future targets. Topics of the Special Issue include, but are not limited to, emerging drug targets; novel drug delivery systems; new drug candidates; and old drug repurposing for eye diseases. The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editor

Dr. Hongli Wu

Department of Pharmaceutical Sciences, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145264

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)